跳至主要内容
临床试验/NCT03881644
NCT03881644已完成不适用

Investigation of PACAP38 Induced Headache, Migraine and Flushing in Patients With Migraine

Danish Headache Center1 个研究点 分布在 1 个国家目标入组 37 人开始时间: 2018年7月17日最近更新:
适应症
干预措施
相关药物

试验速览

阶段
不适用
状态
已完成
入组人数
37
试验地点
1
主要终点
Incidence of migraine

研究概览

简要总结

The aim is to investigate the incidence of headache, migraine attacks and flushing after pituitary adenylate cyclase-activating peptide-38 (PACAP38) with and without treatment with sumatriptan in patients with migraine

详细描述

Pituitary adenylate cyclase-activating peptide-38 (PACAP38) plays a role in migraine pathophysiology. Infusions of PACAP38 can trigger migraine-like attacks in some migraine patients and will induce flushing in all patients. We are investigating whether treatment with sumatriptan has an effect on the PACAP38-induced flushing and on whether headache and migraine is induced.

The purpose of this study is to investigate PACAP38-induced headache and migraine in patients with migraine who have been treated with either sumatriptan or placebo using purpose-developed standardized interview. The study will be conducted with a double-blind, placebo-controlled crossover study design.

研究设计

研究类型
Interventional
分配方式
Randomized
干预模型
Crossover
主要目的
Treatment
盲法
Double (Participant, Investigator)

入排标准

年龄范围
18 Years 至 60 Years(Adult)
性别
All
接受健康志愿者

入选标准

  • diagnosis of migraine, according to IHS criteria
  • weight between 50 - 100 kilograms
  • women in fertile age must not be pregnant and must use adequate contraception

排除标准

  • migraine more than 5 days per month in average over the past year
  • any primary headache other than migraine, apart from tension-type headache which must be less than 5 days per month
  • headache < 48 hours before experimental day
  • migraine < 72 hours before each experimental day
  • daily / frequent use of any medication apart from contraceptive medication
  • use of any drug less than 5 times the half-life of the drug at the time of the experiment
  • women who are pregnant or breast-feeding at the time of the experiment
  • anamnestic or clinical signs of hypertension (systolic blood pressure > 150 mmHg and/or
  • diastolic blood pressure > 100 mmHg) or hypotension (systolic blood pressure < 90 mmHg and/or diastolic blood pressure < 50 mmHg)
  • anamnestic or clinical signs of mental illness, or abuse of alcohol / drugs
  • patients with glaucoma or prostate hyperplasia
  • anamnestic or clinical symptoms of any sort that the investigating doctor deemed unfit for participating in the study

研究组 & 干预措施

PACAP38 + Imigran

Active Comparator

Pituitary adenylate cyclase-activating peptide-38 infusion (10 picomol/kg/min) for 20 mins

AND

Imigran infusion (0.4 mg/min) for 10 mins

干预措施: Imigran (Drug)

PACAP38 + Imigran

Active Comparator

Pituitary adenylate cyclase-activating peptide-38 infusion (10 picomol/kg/min) for 20 mins

AND

Imigran infusion (0.4 mg/min) for 10 mins

干预措施: Pituitary adenylate cyclase-activating peptide-38 (Other)

PACAP38 + Isotonic Saline

Placebo Comparator

Pituitary adenylate cyclase-activating peptide-38 infusion (10 picomol/kg/min) for 20 mins

AND

Isotonic saline for 10 mins (placebo)

干预措施: Isotonic Saline (Other)

PACAP38 + Isotonic Saline

Placebo Comparator

Pituitary adenylate cyclase-activating peptide-38 infusion (10 picomol/kg/min) for 20 mins

AND

Isotonic saline for 10 mins (placebo)

干预措施: Pituitary adenylate cyclase-activating peptide-38 (Other)

结局指标

主要结局

Incidence of migraine

时间窗: From 0 to 12 hours after infusion

Incidence of migraine after PACAP38-infusion will be estimated through a standardized interview based on the international headache classification for migraine

Effect of Sumatriptan

时间窗: From 0 to 12 hours after infusion

Severity of PACAP38-induced headache and migraine after pretreatment with sumatriptan in migraine patients measured by numerical rating scale for pain from 0 ("no pain") to 10 ("worst pain imaginable")

次要结局

  • Severity of headache(From 0 to 12 hours after infusion)
  • Facial temperature(From 0 to 4 hours after infusion)
  • Superficial temporal artery diameter(From 0 to 4 hours after infusion)
  • Severity of flushing(From 0 to 4 hours after infusion)

研究者

申办方类型
Other
责任方
Principal Investigator
主要研究者

Nita Katarina Frifelt Wienholtz

Principal Investigator, Medical Doctor, PhD Student

Danish Headache Center

研究点 (1)

Loading locations...

相似试验

PACAP38 Induced Headache, Migraine and Flushing in... | 临床试验